Mable
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mable - overview
Established
2019
Location
San Francisco, CA, US
Primary Industry
Healthcare IT
About
Founded in 2019 by Inna Nicole Thalmann, and Roman Rothaermel (CEO), and based in California, US, Neurolytic Healthcare, Inc. , trading under the name Mable, operates as a health tech company that provides genomics-based telehealth services for migraine care. In July 2022, Neurolytic Healthcare, Inc. raised USD 3.
2 million in seed funding led by investor Initialized Capital, with participation from an individual investor and Arkitekt Ventures and First In Capital. The firm operates a platform that collects a combination of genetic and biomarker data to extract insights to offer enhanced diagnostics and provide personalized treatment for various neurological conditions. The platform offers online medical consultation services that include DNA testing services and offers precision and preventive treatment based on the DNA results for patients. The firm earns its revenue by offering its software and services at USD 279/month.
The company intends to use the July 2022 financing for operation and business expansion.
Current Investors
Illumina, Inc., Y Combinator, Initialized Capital
Primary Industry
Healthcare IT
Sub Industries
Molecular Science, Genetics & Gene Therapy, Alternative Medicine, Healthcare IT, Medical Software
Website
www.trymable.com
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Mable - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.